Advice

The Marketing Authorisation for this product has been withdrawn

Medicine details

Medicine name:
Lumiracoxib 100mg tablets (Prexige®)
SMC ID:
245/06
Indication:
Symptomatic relief in the treatment of osteoarthritis
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full submission
Status
Withdrawn
Date advice published:
13 March 2006
Additional notes

The marketing authorisation for lumiracoxib (Prexige) has been withdrawn

The European Medicines Agency (EMEA) has completed a review of the safety of medicines containing lumiracoxib. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of these medicines no longer outweigh their risks, and that all marketing authorisations should be withdrawn (revoked) throughout Europe.